These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiac transplantation--1980: The Medical College of Virginia program. Hastillo A; Hess ML; Richardson DW; Lower RR South Med J; 1980 Jul; 73(7):909-11. PubMed ID: 6992284 [TBL] [Abstract][Full Text] [Related]
4. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy. Fisher PE; Suciu-Foca N; Ho E; Michler RE; Rose EA; Mancini D J Heart Lung Transplant; 1995; 14(6 Pt 1):1156-61. PubMed ID: 8719463 [TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256 [TBL] [Abstract][Full Text] [Related]
6. Heart transplantation in Norway. Morphological monitoring of cardiac allograft rejection. A 3-year follow-up. Foerster A; Simonsen S; Frøysaker T APMIS; 1988 Jan; 96(1):14-24. PubMed ID: 3278719 [TBL] [Abstract][Full Text] [Related]
7. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3. Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746 [TBL] [Abstract][Full Text] [Related]
10. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Yamaura K; Ito K; Tsukioka K; Wada Y; Makiuchi A; Sakaguchi M; Akashima T; Fujimori M; Sawa Y; Morishita R; Matsumoto K; Nakamura T; Suzuki J; Amano J; Isobe M Circulation; 2004 Sep; 110(12):1650-7. PubMed ID: 15364799 [TBL] [Abstract][Full Text] [Related]
16. Predictive implications of bioptic diagnosis in cardiac allografts. Kemnitz J; Choritz H; Cohnert TR; Haverich A; Borst HG; Georgii A J Heart Transplant; 1989; 8(4):315-29. PubMed ID: 2671317 [TBL] [Abstract][Full Text] [Related]
17. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480 [TBL] [Abstract][Full Text] [Related]
18. Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy. Thomas F; Cunningham P; Thomas J; Gross U; Gaskins D; Sash C; Parker K Transplant Proc; 1987 Feb; 19(1 Pt 3):1874-8. PubMed ID: 3547892 [No Abstract] [Full Text] [Related]
19. The postsurgical heart. The pathology of cardiac transplantation. Billingham ME Am J Cardiovasc Pathol; 1988; 1(3):319-34. PubMed ID: 3061403 [TBL] [Abstract][Full Text] [Related]
20. Cardiac transplantation for endstage heart disease. Argenziano M; Michler RE; Rose EA Heart Vessels; 1997; Suppl 12():23-7. PubMed ID: 9476536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]